CT Radiomics Models Did Not Outperform Experts in Predicting [68Ga]Ga-PSMA-PET Positivity in Prostate Cancer Lymph Node Staging
<b>Background</b>: The use of [<sup>68</sup>Ga]Ga-PSMA-PET/CT for prostate cancer (PCa) staging is limited by cost and availability. This study evaluates whether radiomic features from contrast-enhanced (CE) CT can predict PSMA-positive lymph nodes (LNs) as a surrogate for metastasis. <b>Methods</b>: A retrospective study of 447 patients included 2537 segmented LNs (425 PET-positive, 2112 PET-negative). Two uroradiologists assessed 417 LNs on CE-CT using a four-point Likert scale. Radiomic features were extracted, selected using four algorithms, and analyzed with six model-building methods. Model performance was compared to radiologist ratings. <b>Results</b>: Radiomic models achieved an accuracy of 0.77-0.85, sensitivity of 0.85-0.91, and specificity of 0.74-0.85. Compared to radiologists, models had higher NPV (0.97-0.98 vs. 0.96) and sensitivity (0.85-0.91 vs. 0.76), but radiologists had superior accuracy (0.95 vs. 0.77-0.85) and specificity (0.97-0.98 vs. 0.74-0.85). In a subanalysis of LNs rated as probably benign or malignant, expert radiologists outperformed the algorithm with greater specificity and PPV (<i>p</i> < 0.005). A density threshold of >27 HU predicted PSMA-positive LNs with 0.79 accuracy, 0.87 sensitivity, and 0.78 specificity. <b>Conclusions</b>: While radiomics did not outperform expert radiologists, the single first-order parameter CT density >27 HU was predictive of PSMA-positive LNs. <b>Clinical Relevance Statement:</b> Radiomic models did not outperform expert uroradiologists. However, in high-volume or resource-limited settings lacking access to [<sup>68</sup>Ga]Ga-PSMA-PET/CT, they may help improve LN assessment in PCa patients with CT alone.
Authors
- Tobias Penzkofer (ORCID: https://orcid.org/0000-0001-9591-8575)
- Holger Amthauer (ORCID: https://orcid.org/0000-0003-4414-0657)
- Boris Gorodetski
- Charlie Alexander Hamm (ORCID: https://orcid.org/0000-0003-4104-4758)
- Alexander Hartenstein (ORCID: https://orcid.org/0000-0001-7238-6051)
- Imke Schatka (ORCID: https://orcid.org/0000-0002-2628-6145)
- Thula Cannon Walter-Rittel
- Julian Rogasch
- Marcus Makowski
Institutions
- TUM Klinikum (DE)
- Humboldt-Universität zu Berlin (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- Bayer (Germany) (DE)
Publication Details
- Journal
- Current Oncology
- Published
- 2026-03-02
- DOI
- https://doi.org/10.3390/curroncol33030146
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- European Commission
- Deutsche Forschungsgemeinschaft
- Bundesministerium für Bildung und Forschung
- Siemens Healthineers
- Berlin Institute of Health
- Horizon 2020 Framework Programme